Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Postprandial glucose regulation: new data and new implications.

Lawrence A Leiter1, Antonio Ceriello, Jaime A Davidson

  • 1St. Michael's Hospital, University of Toronto, Toronto, Canada. leiter@smh.toronto.on.ca

Clinical Therapeutics
|March 8, 2006
PubMed
Summary

Type 2 diabetes management should include postprandial glucose (PPG) monitoring, as it significantly impacts glycemic load and cardiovascular risk. Targeting PPG improves control and reduces atherosclerosis progression, offering better outcomes than relying solely on fasting plasma glucose (FPG) and HbA1c.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Micro- and nano-plastics in the coronary circulation and air pollution exposure in ischaemic heart disease presentation.

European heart journal·2026
Same author

Quality of care for migrant populations with type 2 diabetes mellitus in Italy: a retrospective analysis of data from the the Italian AMD (Associations of Medical Diabetologists) annals initiative.

Acta diabetologica·2026
Same author

Association between electronic cigarette use and prediabetes, diabetes, and insulin resistance: a systematic review and meta-analysis.

Internal and emergency medicine·2026
Same author

Causes and consequences of discontinuation of GLP1RAs or tirzepatide.

Nature reviews. Endocrinology·2026
Same author

A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.

The lancet. Diabetes & endocrinology·2026
Same author

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

Cardiovascular diabetology·2026

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Cardiovascular Disease

Background:

  • Type 2 diabetes is primarily a disorder of postprandial glucose (PPG) regulation due to declining insulin secretion.
  • Current management often overlooks PPG, focusing instead on fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c).

Purpose of the Study:

  • To review data on postprandial hyperglycemia.
  • To assess if and how type 2 diabetes management should incorporate PPG findings.

Main Methods:

  • Literature review of MEDLINE searches and personal references.
  • Emphasis on postprandial hyperglycemia's contribution to glycemic load and cardiovascular (CV) risk.

Main Results:

  • 33% of type 2 diabetes patients have normal FPG but abnormal PPG.

Related Experiment Videos

  • PPG contributes over 70% to glycemic load in well-controlled patients (HbA1c <7.3%).
  • Increased CV mortality risk correlates linearly with 2-hour oral glucose tolerance test (OGTT) levels, even below diagnostic thresholds.
  • Specific therapies targeting PPG (biphasic insulin aspart, repaglinide, acarbose) demonstrated improved glycemic control, reduced endothelial dysfunction, atherosclerosis regression, and decreased CV events compared to other treatments or placebo.

    • Conclusions:

    • All glucose measures—FPG, HbA1c, and PPG—are crucial for type 2 diabetes management.
    • Therapies targeting PPG improve glucose control, reduce atherosclerosis, and decrease CV events.
    • Physicians should consider monitoring and managing PPG alongside FPG and HbA1c.